MANTLE CELL LYMPHOMA (MCL)
Clinical trials for MANTLE CELL LYMPHOMA (MCL) explained in plain language.
Never miss a new study
Get alerted when new MANTLE CELL LYMPHOMA (MCL) trials appear
Sign up with your email to follow new studies for MANTLE CELL LYMPHOMA (MCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
CAR-T therapy shows promise in Long-Term Follow-Up for blood cancers
Disease control CompletedThis study followed 16 patients with various B-cell cancers (like lymphoma and leukemia) who had already received CLBR001 CAR-T cells. The goal was to check for long-term side effects and see how well the treatment controlled the disease over time. Researchers monitored new or la…
Matched conditions: MANTLE CELL LYMPHOMA (MCL)
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Disease control
Last updated May 26, 2026 08:29 UTC
-
New hope for tough blood cancers: experimental drug PRT2527 tested in early trial
Disease control CompletedThis early-stage study tested a new drug called PRT2527, alone or combined with other medicines (zanubrutinib or venetoclax), in 86 people with blood cancers that returned or didn't respond to standard treatments. The main goals were to check safety, find the best dose, and see i…
Matched conditions: MANTLE CELL LYMPHOMA (MCL)
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated May 22, 2026 14:05 UTC
-
New drug combo shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis study tested a combination of two drugs, acalabrutinib and pembrolizumab, in 161 people with different types of blood cancers like lymphoma and leukemia. The main goal was to check safety and see how well the drugs worked together. Researchers measured side effects and tumor…
Matched conditions: MANTLE CELL LYMPHOMA (MCL)
Phase: PHASE1, PHASE2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated May 22, 2026 13:53 UTC